Boston Scientific Corporation (BSX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Boston Scientific Corporation (BSX) trades at $45.14 with AI Score 82/100 (Grade A+). Boston Scientific Corporation is a leading developer and manufacturer of medical devices across various interventional medical specialties. Market cap: $67.09B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026BSX stock analysis for 2026: Analysts have set a consensus price target of $107.79 for Boston Scientific Corporation, suggesting 138.8% upside from the current price of $45.14. The AI MoonshotScore is 82/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
BSX: 5/7 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →Boston Scientific Corporation (BSX) Healthcare & Pipeline Overview
Boston Scientific Corporation excels in the development and manufacturing of innovative medical devices, addressing critical healthcare needs across multiple specialties, including cardiovascular, rhythm management, and surgical interventions, while maintaining a robust market presence and a commitment to improving patient outcomes.
What Is the Investment Thesis for BSX?
Boston Scientific Corporation is poised for continued growth driven by its robust product pipeline and strategic focus on innovation. The company has a market capitalization of $67.09B and a P/E ratio of 11.9, reflecting investor confidence in its long-term prospects. Key value drivers include a profit margin of 17.2% and a gross margin of 70.4%, which indicate operational efficiency and strong pricing power. Growth catalysts include the increasing demand for minimally invasive procedures, advancements in cardiac and neurological technologies, and expansion into emerging markets. The company’s commitment to enhancing patient outcomes through innovative solutions positions it well to capitalize on the projected growth of the global medical device market, which is expected to reach $600 billion by 2025. However, potential risks include regulatory challenges and competition from other industry players.
Based on FMP financials and quantitative analysis
BSX Key Highlights
- Market capitalization of $67.09B, indicating a strong market presence.
- P/E ratio of 11.9, reflecting investor confidence in growth potential.
- Profit margin of 17.2%, showcasing operational efficiency.
- Gross margin of 70.4%, exceeding industry averages and indicating strong pricing power.
- A workforce of 53,000 employees, underscoring the company's scale and operational capabilities.
Who Are BSX's Competitors?
BSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $374.15 | +3.55% | $201.93B | 83 |
| GILD Gilead Sciences, Inc. | $131.27 | +4.21% | $162.98B | 94 |
| ABT Abbott Laboratories | $95.39 | +3.48% | $166.15B | 70 |
| PFE Pfizer Inc. | $24.32 | +1.84% | $138.61B | 64 |
| DHR Danaher Corporation | $197.93 | +2.17% | $140.09B | 69 |
| DCTH Delcath Systems, Inc. | $13.20 | +2.25% | $455.69M | 73 |
| SSII SS Innovations International, Inc. | $3.78 | -4.06% | $756.50M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BSX's Key Strengths?
- Strong market position with a diverse product portfolio.
- High gross margins indicating operational efficiency.
- Commitment to innovation through significant R&D investment.
- Established global presence with a wide distribution network.
What Are BSX's Weaknesses?
- Dependence on a limited number of product lines for revenue.
- Exposure to regulatory challenges and compliance risks.
- Potential for product recalls impacting brand reputation.
- High competition leading to pricing pressures.
What Could Drive BSX Stock Higher?
- Continued expansion of the product pipeline with new medical devices expected to launch in the next 12 months.
- Strong demand for minimally invasive procedures driving sales growth across multiple segments.
- Strategic partnerships and collaborations enhancing market reach and product development capabilities.
- Anticipated regulatory approvals for new devices that could significantly impact market share.
- Investment in research and development to drive innovation and maintain competitive advantage.
What Are the Key Risks for BSX?
- Regulatory challenges that could delay product launches or approvals.
- Intense competition from other medical device manufacturers impacting pricing and market share.
- Economic downturns affecting healthcare budgets and spending on medical devices.
- Supply chain disruptions that could impact product availability and delivery timelines.
What Are the Growth Opportunities for BSX?
- Growth opportunity 1: The global cardiovascular device market is expected to reach $60 billion by 2025, driven by rising cardiovascular diseases and the demand for advanced treatment options. Boston Scientific's innovative products, such as drug-eluting stents and implantable devices, position the company to capture significant market share in this growing segment.
- Growth opportunity 2: The neuromodulation market, projected to grow to $7 billion by 2025, presents a substantial opportunity for Boston Scientific. With its spinal cord stimulation systems and deep brain stimulation technologies, the company is strategically positioned to meet the increasing demand for chronic pain management solutions.
- Growth opportunity 3: The global market for minimally invasive surgical devices is anticipated to grow at a CAGR of 6.5% through 2026, reaching $50 billion. Boston Scientific's commitment to developing innovative MedSurg products places it in a favorable position to benefit from this trend, particularly in gastrointestinal and urological applications.
- Growth opportunity 4: The expansion into emerging markets, particularly in Asia-Pacific and Latin America, offers significant growth potential. As healthcare infrastructure improves and access to advanced medical technologies increases, Boston Scientific can leverage its expertise to penetrate these markets effectively.
- Growth opportunity 5: The increasing focus on remote patient management and telehealth solutions is expected to drive growth in the healthcare sector. Boston Scientific's investment in remote monitoring technologies positions it to capitalize on this trend, enhancing patient engagement and improving clinical outcomes.
What Opportunities Does BSX Have?
- Growth in emerging markets offering new revenue streams.
- Increasing demand for minimally invasive surgical procedures.
- Expansion of remote patient management technologies.
- Strategic acquisitions to enhance product offerings and market reach.
What Threats Does BSX Face?
- Intense competition from established medical device manufacturers.
- Regulatory changes affecting product approvals and market access.
- Economic downturns impacting healthcare spending.
- Technological advancements by competitors outpacing innovation.
What Are BSX's Competitive Advantages?
- Strong brand recognition and reputation for quality and innovation.
- Extensive patent portfolio protecting proprietary technologies.
- Established relationships with healthcare providers and institutions.
- Robust research and development capabilities driving continuous innovation.
- Diverse product portfolio catering to multiple medical specialties.
What Does BSX Do?
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation has established itself as a global leader in the development, manufacturing, and marketing of medical devices. The company operates through three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Boston Scientific's extensive product portfolio includes devices for diagnosing and treating gastrointestinal and pulmonary conditions, as well as products for urological and pelvic conditions. The company is also known for its implantable cardioverter defibrillators, pacemakers, and advanced remote patient management systems. Over the years, Boston Scientific has expanded its offerings to include cutting-edge technologies for cardiac mapping, navigation solutions, and spinal cord stimulation systems for chronic pain management. The company has continually adapted to the evolving healthcare landscape, focusing on innovation and patient-centric solutions. With a workforce of approximately 53,000 employees, Boston Scientific serves a diverse global market, providing essential medical technologies that enhance patient care and improve clinical outcomes. The company's commitment to research and development has positioned it favorably within the competitive landscape, allowing it to maintain a strong foothold in the rapidly growing medical device industry.
What Products and Services Does BSX Offer?
- Develops and manufactures medical devices for various interventional specialties.
- Offers products for diagnosing and treating gastrointestinal and pulmonary conditions.
- Provides implantable devices for cardiac rhythm management.
- Delivers advanced technologies for spinal cord stimulation and chronic pain management.
- Markets interventional cardiology products, including stents and catheters.
- Focuses on innovative solutions to improve patient outcomes and enhance healthcare delivery.
How Does BSX Make Money?
- Generates revenue through the sale of medical devices across multiple therapeutic areas.
- Operates through three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
- Invests in research and development to drive innovation and expand product offerings.
- Utilizes a global distribution network to reach healthcare providers and patients.
- Focuses on partnerships and collaborations to enhance product development and market reach.
What Industry Does BSX Operate In?
The medical device industry is experiencing significant growth, driven by technological advancements, an aging population, and increasing demand for minimally invasive procedures. The global market for medical devices is projected to reach approximately $600 billion by 2025, with a compound annual growth rate (CAGR) of around 5.4%. Boston Scientific Corporation is well-positioned within this competitive landscape, facing competition from established players such as Amgen Inc. (AMGN), Gilead Sciences, Inc. (GILD), Abbott Laboratories (ABT), Pfizer Inc. (PFE), and Danaher Corporation (DHR). The company's focus on innovation and patient-centric solutions enables it to maintain a competitive edge in a rapidly evolving market.
Who Are BSX's Key Customers?
- Healthcare providers including hospitals and outpatient clinics.
- Physicians and specialists in various medical fields.
- Patients requiring medical interventions for chronic conditions.
- Healthcare systems and payers seeking effective medical solutions.
- Distributors and partners in the medical device supply chain.
Boston Scientific Corporation Financial Trajectory
Boston Scientific Corporation (BSX) reported $5.20B in revenue for Q1 2026, a decline of 1.6% compared to the prior quarter. The company recorded net income of $1.34B, with diluted EPS of $0.90. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BSX averaged $0.59 in diluted EPS.
Company Profile
Boston Scientific Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Marlborough, US. The company is led by CEO Michael F. Mahoney. BSX has traded publicly since 1992.
How Boston Scientific Corporation Is Valued
Boston Scientific Corporation carries a market capitalization of $67.09B, placing it in the large-cap category. Relative to its peer group, BSX's quantitative score of 82/100 is roughly in line with the peer average of 76/100.
ROE 15%Key Financial Metrics
Return on equity for Boston Scientific Corporation stands at 14.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.1%, showing how much profit it generates from its asset base. BSX trades at a trailing price-to-earnings ratio of 11.94, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Boston Scientific Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.32 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Boston Scientific Corporation revenue of about $21.62B for fiscal 2026, with EPS near $3.36. The estimate reflects 22 contributing analysts.
Net sellingInsider Activity
Over the past six months, Boston Scientific Corporation insiders filed 15 SEC Form 4 transactions — 1 sales and 14 purchases. On net that is roughly 351K shares disposed (about $554K), a signal worth weighing alongside the fundamentals.
BSX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Boston Scientific's recent insider buying suggests confidence in the company's future prospects. This can signal that those with the most knowledge about the company believe it's undervalued.
- The overall community sentiment seems to be leaning bullish, with many traders expressing optimism about BSX's long-term growth potential in medical devices.
- BSX is perceived as a stable player in the healthcare sector, which tends to be more resilient during economic downturns, making it an attractive investment. Think of it like Johnson & Johnson, known for its consistent performance.
- There's a growing perception that BSX is well-positioned to benefit from the aging population and increasing demand for medical technologies.
Bear Case
- Some insiders have been selling shares recently, which could indicate concerns about the company's near-term performance or alternative investment opportunities.
- Bearish community members are pointing to potential headwinds from increased competition in the medical device market, squeezing margins.
- There's a market perception that BSX's growth may be limited compared to more innovative, high-growth tech companies, making it less appealing to some investors.
- Concerns are emerging about potential regulatory changes impacting the medical device industry, which could negatively affect BSX's profitability and market access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
From the Earnings Call
“And to that end, we are guiding to organic growth of 5% to 7% for the second quarter and reducing our full year guidance to 6.5% to 8%, reflecting unanticipated headwinds and changing business patterns that I'll cover in more detail on this call.”
— Michael Mahoney, Chairman and Chief Executive Officer
“Our second quarter '26 adjusted EPS guide is $0.82 to $0.84, and we now expect our full year adjusted EPS to be $3.34 to $3.41, representing growth of 9% to 11%.”
— Michael Mahoney, Chairman and Chief Executive Officer
BSX Q1 FY2026 earnings call transcript · 2026-04-22
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $5.20B | $1.34B | $0.90 |
| Q4 2025 | $5.29B | $668M | $0.45 |
| Q3 2025 | $5.07B | $755M | $0.50 |
| Q2 2025 | $5.06B | $793M | $0.53 |
Based on FMP financials and quantitative analysis
BSX Latest News
-
Boston Scientific’s Quarterly Earnings Preview: What You Need to Know
Barchart · Jul 2, 2026
-
Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
Insider Monkey · Jul 1, 2026
-
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Zacks · Jun 30, 2026
-
Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
Insider Monkey · Jun 30, 2026
BSX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSX.
Price Targets
Consensus target: $107.79
BSX MoonshotScore
What does this score mean?
The MoonshotScore rates BSX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Boston Scientific’s Quarterly Earnings Preview: What You Need to Know
Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
Latest Boston Scientific Corporation Analysis
Eli Lilly's Taltz and Zepbound Combo Shows Promise, LLY Dips 2.09%
3 min readMarket Weakness Broadens as SPY Dips 1.71%, QQQ Down 1.95%
2 min readHealthcare Earnings Boost BSX, While EFX Revenue Grows 9% Amid Economic Headwinds
2 min readBitcoin and Ether Rebound Amid Derivatives Risk Reduction
3 min readTech Weakness Drags on Nasdaq, SPY Down 0.85%
3 min readLeadership: Michael F. Mahoney
Chairman and Chief Executive Officer
Michael F. Mahoney has been with Boston Scientific since 2012, bringing over 30 years of experience in the medical device industry. He holds a Bachelor’s degree in Business Administration from the University of Massachusetts Amherst and has held various leadership positions at leading healthcare companies prior to joining Boston Scientific.
Track Record: Under Mahoney's leadership, Boston Scientific has achieved significant growth, expanding its product portfolio and entering new markets. His strategic focus on innovation has driven the company’s research initiatives and enhanced its competitive positioning in the medical device sector.
Boston Scientific Corporation Healthcare Stock: Key Questions Answered
What does Boston Scientific Corporation do?
Boston Scientific Corporation develops and manufactures a wide range of medical devices for various interventional specialties, including cardiovascular, rhythm management, and surgical interventions. The company’s products are designed to diagnose and treat conditions in areas such as gastrointestinal, pulmonary, urology, and chronic pain management, contributing to improved patient outcomes.
What do analysts say about BSX stock?
Analysts generally view Boston Scientific Corporation positively, citing its strong market position and growth potential driven by innovation in medical devices. Key valuation metrics such as a P/E ratio of 11.9 suggest that the stock is valued in line with industry peers, while the company's focus on expanding its product offerings and market presence is seen as a positive growth consideration.
What are the main risks for BSX?
Boston Scientific Corporation faces several risks, including regulatory challenges that may delay product approvals and impact market access. Additionally, the competitive landscape poses a threat, with numerous established players vying for market share. Economic fluctuations could also affect healthcare spending, while potential supply chain disruptions may impact product availability.
What are the key factors to evaluate for BSX?
Boston Scientific Corporation (BSX) holds an AI score of 82/100 (high). P/E: 11.9x vs the S&P 500's ~20-25x. Analysts target $107.79 (+139%). Not financial advice.
How frequently does BSX data refresh on this page?
BSX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BSX's recent stock price performance?
Boston Scientific Corporation (BSX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position with a diverse product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BSX overvalued or undervalued right now?
Boston Scientific Corporation (BSX) trades at 11.9x earnings. Analysts target $107.79 (+139%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BSX?
Before investing in Boston Scientific Corporation (BSX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company reports and industry analysis.